Dorff Tanya B, Quek Marcus L, Daneshmand Siamak, Pinski Jacek
University of Southern California, Norris Comprehensive Cancer Center, Division of Medical Oncology, Los Angeles, CA, USA.
Expert Rev Anticancer Ther. 2006 Nov;6(11):1639-51. doi: 10.1586/14737140.6.11.1639.
While men with early stage prostate cancer typically enjoy long-term survival after definitive management, for those who present with locally advanced or metastatic disease, survival is compromised. Multimodality therapy can prolong survival in these patients, with state-of-the-art options including intensity-modulated radiation or brachytherapy in conjunction with androgen ablation, adjuvant androgen ablation and/or chemotherapy with radical retropubic prostatectomy. In addition, novel biological therapies are being explored to target the unique molecular changes in prostate cancer cells and their interactions with the microenvironment. With these advances the outlook will undoubtedly improve, even for patients presenting with advanced disease. Careful application of these emerging therapies to a select group of prostate cancer patients most likely to obtain benefit from them is the challenge for urologists, medical oncologists and radiation oncologists for the future.
虽然早期前列腺癌男性患者在进行确定性治疗后通常能长期存活，但对于那些出现局部晚期或转移性疾病的患者，生存率会受到影响。多模式治疗可延长这些患者的生存期，目前的先进治疗方案包括调强放疗或近距离放疗联合雄激素剥夺、辅助雄激素剥夺和/或与根治性耻骨后前列腺切除术联合的化疗。此外，正在探索新型生物疗法，以针对前列腺癌细胞的独特分子变化及其与微环境的相互作用。随着这些进展，即使是患有晚期疾病的患者，前景无疑也会改善。对泌尿外科医生、医学肿瘤学家和放射肿瘤学家来说，未来的挑战在于谨慎地将这些新兴疗法应用于最有可能从中获益的特定前列腺癌患者群体。
